Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/anti-CD22 CAR T cells

A preparation of human T lymphocytes engineered to express chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) cluster of differentiation 20 (CD20) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD20/anti-CD22 CAR T cells target and bind to both CD20 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD20 and CD22 are overexpressed in certain hematologic malignancies.
Synonym:CD20/CD22 dual targeted CAR T cells
CD20/CD22-targeted CAR T cells
Search NCI's Drug Dictionary